IMTX vs. IMVT, DNLI, SWTX, ACLX, TWST, APGE, NVAX, CGON, ADMA, and VCEL
Should you be buying Immatics stock or one of its competitors? The main competitors of Immatics include Immunovant (IMVT), Denali Therapeutics (DNLI), SpringWorks Therapeutics (SWTX), Arcellx (ACLX), Twist Bioscience (TWST), Apogee Therapeutics (APGE), Novavax (NVAX), CG Oncology (CGON), ADMA Biologics (ADMA), and Vericel (VCEL). These companies are all part of the "biological products, except diagnostic" industry.
Immunovant (NASDAQ:IMVT) and Immatics (NASDAQ:IMTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.
Immunovant received 86 more outperform votes than Immatics when rated by MarketBeat users. Likewise, 76.71% of users gave Immunovant an outperform vote while only 72.22% of users gave Immatics an outperform vote.
47.1% of Immunovant shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 4.8% of Immunovant shares are owned by company insiders. Comparatively, 3.3% of Immatics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Immunovant has a net margin of 0.00% compared to Immunovant's net margin of -107.80%. Immunovant's return on equity of -29.36% beat Immatics' return on equity.
Immatics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.
Immunovant currently has a consensus price target of $48.75, suggesting a potential upside of 93.68%. Immatics has a consensus price target of $16.00, suggesting a potential upside of 21.58%. Given Immatics' higher possible upside, equities research analysts plainly believe Immunovant is more favorable than Immatics.
Immunovant has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Immatics has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.
In the previous week, Immunovant had 5 more articles in the media than Immatics. MarketBeat recorded 9 mentions for Immunovant and 4 mentions for Immatics. Immunovant's average media sentiment score of 1.05 beat Immatics' score of 0.75 indicating that Immatics is being referred to more favorably in the news media.
Summary
Immatics beats Immunovant on 9 of the 16 factors compared between the two stocks.
Get Immatics News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immatics Competitors List
Related Companies and Tools
